schliessen

Filtern

 

Bibliotheken

The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

Aims/hypothesis Some studies have reported that annual change in eGFR (eGFR slope) is associated with the future risk of end-stage kidney disease, cardiovascular disease and death in general or chronic kidney disease cohorts. However, the benefits of using eGFR slopes for prediction of major clinica... Full description

Journal Title: Diabetologia 2019, Vol.62 (11), p.1988-1997
Main Author: Oshima, Megumi
Other Authors: Jun, Min , Ohkuma, Toshiaki , Toyama, Tadashi , Wada, Takashi , Cooper, Mark E , Hadjadj, Samy , Hamet, Pavel , Harrap, Stephen , Mancia, Giuseppe , Marre, Michel , Williams, Bryan , Chalmers, John , Woodward, Mark , Perkovic, Vlado
Format: Electronic Article Electronic Article
Language: English
Subjects:
End
Publisher: Berlin/Heidelberg: Springer Berlin Heidelberg
ID: ISSN: 0012-186X
Link: https://www.ncbi.nlm.nih.gov/pubmed/31302707
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6805825
title: The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
format: Article
creator:
  • Oshima, Megumi
  • Jun, Min
  • Ohkuma, Toshiaki
  • Toyama, Tadashi
  • Wada, Takashi
  • Cooper, Mark E
  • Hadjadj, Samy
  • Hamet, Pavel
  • Harrap, Stephen
  • Mancia, Giuseppe
  • Marre, Michel
  • Williams, Bryan
  • Chalmers, John
  • Woodward, Mark
  • Perkovic, Vlado
subjects:
  • Article
  • Cardiovascular disease
  • Cardiovascular diseases
  • Creatinine
  • Diabetes
  • Diabetes mellitus
  • Diabetes mellitus (non-insulin dependent)
  • Diuretics
  • eGFR slope
  • End
  • End-stage kidney disease
  • End-stage renal disease
  • Epidermal growth factor receptors
  • Health aspects
  • Health risk assessment
  • Human Physiology
  • Internal Medicine
  • Kidney diseases
  • Kidneys
  • Medicine
  • Medicine & Public Health
  • Metabolic Diseases
  • Mortality
  • Regression analysis
  • stage kidney disease
  • Surrogate endpoint
  • Type 2 diabetes
  • Vascular diseases
ispartof: Diabetologia, 2019, Vol.62 (11), p.1988-1997
description: Aims/hypothesis Some studies have reported that annual change in eGFR (eGFR slope) is associated with the future risk of end-stage kidney disease, cardiovascular disease and death in general or chronic kidney disease cohorts. However, the benefits of using eGFR slopes for prediction of major clinical outcomes in diabetes are unclear. Methods We used data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial and the ADVANCE Post-Trial Observational Study (ADVANCE-ON). After excluding the first 4 months during which an acute fall in eGFR was induced by the initiation of an ACE inhibitor and diuretic combination agent, eGFR slopes were estimated by linear mixed models, using three measurements of eGFR at 4, 12 and 24 months after randomisation over 20 months, and categorised according to quartiles. Cox regression models were used to evaluate adjusted HRs for the study’s primary outcome, a composite of major renal events, major macrovascular events and all-cause mortality during the subsequent follow-up from 24 months after randomisation. Results A total of 8,879 participants (80%) were included in this cohort. The mean age was 65.6 years (SD 6.3), the mean eGFR was 75 ml min −1 (1.73 m) −2 (SD 17) and the median urinary albumin/creatinine ratio was 14 μg/mg (interquartile range 7–38). The mean eGFR slope was −0.63 ml min −1 (1.73 m) −2  year −1 (SD 1.75). Over a median follow-up of 7.6 years following the 20-month eGFR slope ascertainment period, 2,221 participants (25%) met the primary outcome. An annual substantial decrease in eGFR (lowest 25%, 0.33) had no significant association with the risk of the primary outcome (HR 0.96 [95% CI 0.86, 1.07]). Conclusions/interpretation Our study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality. Trial registry number ClinicalTrials.gov registration no. NCT00145925 and no. NCT00949286
language: eng
source:
identifier: ISSN: 0012-186X
fulltext: no_fulltext
issn:
  • 0012-186X
  • 1432-0428
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.656526
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6805825
sourceformatXML
sourcesystemPC
galeidA603510686
sourcerecordidA603510686
originalsourceidFETCH-LOGICAL-1565t-ff07cb7974333cface6d9debdfaf9de24eaae3b5a8c9ad9195ee987ffd8bcb7c0
addsrcrecordideNp1ktFuFCEUhidGY2v1AbwxRG-8mQozzAx40WSzttWk2SamGu8IA4dd6iyswLTZh_CdZZ1aXaPhgoTz_T-cw18Uzwk-Jhh3byLGpGpKTHhJOWUlfVAcElpXJaYVe1gc7solYe2Xg-JJjNcY47qh7ePioCY1rjrcHRbfr1aAAgwyWe_iym5QD-kWwCE4P_uI4uA3gKTTKI59hG8juISCjV-RN-hGRjUOMiA_JuXXEH-CchhKJccIaO1DkoNNW2QdSttsVCFtZb4A4luU8sWzd59ni_lpeblAMY16-7R4ZOQQ4dndflR8Oju9mr8vLy7PP8xnFyVp2iaVxuBO9R3vaF3XykgFreYaem2kyXtFQUqo-0YyxaXmhDcAnHXGaNZnncJHxcnkuxn7NWiVuwpyEJtg1zJshZdW7FecXYmlvxEtww2rmmywmAzyeJy0Afa02kESGvS4EbdG5F8QPD-JsY4QTmiruJGUaN2qvjWcas27bPj67kXB5ynHJNY2KhgG6cCPUVRVw0jDaU0y-vIv9NqPweV5iYrUjLZdjTP0aoKWcgBhnfG5D7XzFLM2x4DglrWZOv4HlZeGtVXegbH5fE9AJoEKPsYA5r5vgsUuk2LKpMiZFLtMCpo1L_4c9r3iVwgzUE1AzCW3hPC7of-7_gBlVO2u
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid213846730
display
typearticle
titleThe relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
creatorOshima, Megumi ; Jun, Min ; Ohkuma, Toshiaki ; Toyama, Tadashi ; Wada, Takashi ; Cooper, Mark E ; Hadjadj, Samy ; Hamet, Pavel ; Harrap, Stephen ; Mancia, Giuseppe ; Marre, Michel ; Williams, Bryan ; Chalmers, John ; Woodward, Mark ; Perkovic, Vlado
creatorcontribOshima, Megumi ; Jun, Min ; Ohkuma, Toshiaki ; Toyama, Tadashi ; Wada, Takashi ; Cooper, Mark E ; Hadjadj, Samy ; Hamet, Pavel ; Harrap, Stephen ; Mancia, Giuseppe ; Marre, Michel ; Williams, Bryan ; Chalmers, John ; Woodward, Mark ; Perkovic, Vlado ; ADVANCE Collaborative Group ; on behalf of the ADVANCE Collaborative Group
descriptionAims/hypothesis Some studies have reported that annual change in eGFR (eGFR slope) is associated with the future risk of end-stage kidney disease, cardiovascular disease and death in general or chronic kidney disease cohorts. However, the benefits of using eGFR slopes for prediction of major clinical outcomes in diabetes are unclear. Methods We used data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial and the ADVANCE Post-Trial Observational Study (ADVANCE-ON). After excluding the first 4 months during which an acute fall in eGFR was induced by the initiation of an ACE inhibitor and diuretic combination agent, eGFR slopes were estimated by linear mixed models, using three measurements of eGFR at 4, 12 and 24 months after randomisation over 20 months, and categorised according to quartiles. Cox regression models were used to evaluate adjusted HRs for the study’s primary outcome, a composite of major renal events, major macrovascular events and all-cause mortality during the subsequent follow-up from 24 months after randomisation. Results A total of 8,879 participants (80%) were included in this cohort. The mean age was 65.6 years (SD 6.3), the mean eGFR was 75 ml min −1 (1.73 m) −2 (SD 17) and the median urinary albumin/creatinine ratio was 14 μg/mg (interquartile range 7–38). The mean eGFR slope was −0.63 ml min −1 (1.73 m) −2  year −1 (SD 1.75). Over a median follow-up of 7.6 years following the 20-month eGFR slope ascertainment period, 2,221 participants (25%) met the primary outcome. An annual substantial decrease in eGFR (lowest 25%, <−1.63 ml min −1 [1.73 m] −2  year −1 ) was significantly associated with the subsequent risk of the primary outcome (HR 1.30 [95% CI 1.17, 1.43]) compared with a stable change in eGFR (middle 50%, −1.63 to 0.33). An annual substantial increase in eGFR (highest 25%, >0.33) had no significant association with the risk of the primary outcome (HR 0.96 [95% CI 0.86, 1.07]). Conclusions/interpretation Our study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality. Trial registry number ClinicalTrials.gov registration no. NCT00145925 and no. NCT00949286
identifier
0ISSN: 0012-186X
1EISSN: 1432-0428
2DOI: 10.1007/s00125-019-4948-4
3PMID: 31302707
languageeng
publisherBerlin/Heidelberg: Springer Berlin Heidelberg
subjectArticle ; Cardiovascular disease ; Cardiovascular diseases ; Creatinine ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diuretics ; eGFR slope ; End ; End-stage kidney disease ; End-stage renal disease ; Epidermal growth factor receptors ; Health aspects ; Health risk assessment ; Human Physiology ; Internal Medicine ; Kidney diseases ; Kidneys ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Mortality ; Regression analysis ; stage kidney disease ; Surrogate endpoint ; Type 2 diabetes ; Vascular diseases
ispartofDiabetologia, 2019, Vol.62 (11), p.1988-1997
rights
0The Author(s) 2019
1COPYRIGHT 2019 Springer
2Diabetologia is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
lds50peer_reviewed
oafree_for_read
citesFETCH-LOGICAL-1565t-ff07cb7974333cface6d9debdfaf9de24eaae3b5a8c9ad9195ee987ffd8bcb7c0
orcidid0000-0002-4108-5229
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31302707$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Oshima, Megumi
1Jun, Min
2Ohkuma, Toshiaki
3Toyama, Tadashi
4Wada, Takashi
5Cooper, Mark E
6Hadjadj, Samy
7Hamet, Pavel
8Harrap, Stephen
9Mancia, Giuseppe
10Marre, Michel
11Williams, Bryan
12Chalmers, John
13Woodward, Mark
14Perkovic, Vlado
15ADVANCE Collaborative Group
16on behalf of the ADVANCE Collaborative Group
title
0The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
1Diabetologia
addtitle
0Diabetologia
1Diabetologia
descriptionAims/hypothesis Some studies have reported that annual change in eGFR (eGFR slope) is associated with the future risk of end-stage kidney disease, cardiovascular disease and death in general or chronic kidney disease cohorts. However, the benefits of using eGFR slopes for prediction of major clinical outcomes in diabetes are unclear. Methods We used data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial and the ADVANCE Post-Trial Observational Study (ADVANCE-ON). After excluding the first 4 months during which an acute fall in eGFR was induced by the initiation of an ACE inhibitor and diuretic combination agent, eGFR slopes were estimated by linear mixed models, using three measurements of eGFR at 4, 12 and 24 months after randomisation over 20 months, and categorised according to quartiles. Cox regression models were used to evaluate adjusted HRs for the study’s primary outcome, a composite of major renal events, major macrovascular events and all-cause mortality during the subsequent follow-up from 24 months after randomisation. Results A total of 8,879 participants (80%) were included in this cohort. The mean age was 65.6 years (SD 6.3), the mean eGFR was 75 ml min −1 (1.73 m) −2 (SD 17) and the median urinary albumin/creatinine ratio was 14 μg/mg (interquartile range 7–38). The mean eGFR slope was −0.63 ml min −1 (1.73 m) −2  year −1 (SD 1.75). Over a median follow-up of 7.6 years following the 20-month eGFR slope ascertainment period, 2,221 participants (25%) met the primary outcome. An annual substantial decrease in eGFR (lowest 25%, <−1.63 ml min −1 [1.73 m] −2  year −1 ) was significantly associated with the subsequent risk of the primary outcome (HR 1.30 [95% CI 1.17, 1.43]) compared with a stable change in eGFR (middle 50%, −1.63 to 0.33). An annual substantial increase in eGFR (highest 25%, >0.33) had no significant association with the risk of the primary outcome (HR 0.96 [95% CI 0.86, 1.07]). Conclusions/interpretation Our study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality. Trial registry number ClinicalTrials.gov registration no. NCT00145925 and no. NCT00949286
subject
0Article
1Cardiovascular disease
2Cardiovascular diseases
3Creatinine
4Diabetes
5Diabetes mellitus
6Diabetes mellitus (non-insulin dependent)
7Diuretics
8eGFR slope
9End
10End-stage kidney disease
11End-stage renal disease
12Epidermal growth factor receptors
13Health aspects
14Health risk assessment
15Human Physiology
16Internal Medicine
17Kidney diseases
18Kidneys
19Medicine
20Medicine & Public Health
21Metabolic Diseases
22Mortality
23Regression analysis
24stage kidney disease
25Surrogate endpoint
26Type 2 diabetes
27Vascular diseases
issn
00012-186X
11432-0428
fulltextfalse
rsrctypearticle
creationdate2019
recordtypearticle
recordideNp1ktFuFCEUhidGY2v1AbwxRG-8mQozzAx40WSzttWk2SamGu8IA4dd6iyswLTZh_CdZZ1aXaPhgoTz_T-cw18Uzwk-Jhh3byLGpGpKTHhJOWUlfVAcElpXJaYVe1gc7solYe2Xg-JJjNcY47qh7ePioCY1rjrcHRbfr1aAAgwyWe_iym5QD-kWwCE4P_uI4uA3gKTTKI59hG8juISCjV-RN-hGRjUOMiA_JuXXEH-CchhKJccIaO1DkoNNW2QdSttsVCFtZb4A4luU8sWzd59ni_lpeblAMY16-7R4ZOQQ4dndflR8Oju9mr8vLy7PP8xnFyVp2iaVxuBO9R3vaF3XykgFreYaem2kyXtFQUqo-0YyxaXmhDcAnHXGaNZnncJHxcnkuxn7NWiVuwpyEJtg1zJshZdW7FecXYmlvxEtww2rmmywmAzyeJy0Afa02kESGvS4EbdG5F8QPD-JsY4QTmiruJGUaN2qvjWcas27bPj67kXB5ynHJNY2KhgG6cCPUVRVw0jDaU0y-vIv9NqPweV5iYrUjLZdjTP0aoKWcgBhnfG5D7XzFLM2x4DglrWZOv4HlZeGtVXegbH5fE9AJoEKPsYA5r5vgsUuk2LKpMiZFLtMCpo1L_4c9r3iVwgzUE1AzCW3hPC7of-7_gBlVO2u
startdate20190713
enddate20190713
creator
0Oshima, Megumi
1Jun, Min
2Ohkuma, Toshiaki
3Toyama, Tadashi
4Wada, Takashi
5Cooper, Mark E
6Hadjadj, Samy
7Hamet, Pavel
8Harrap, Stephen
9Mancia, Giuseppe
10Marre, Michel
11Williams, Bryan
12Chalmers, John
13Woodward, Mark
14Perkovic, Vlado
general
0Springer Berlin Heidelberg
1Springer
2Springer Nature B.V
scope
0NPM
1AAYXX
2CITATION
3BSHEE
43V.
57T5
67X7
77XB
888E
98AO
108C1
118FI
128FJ
138FK
14ABUWG
15BENPR
16FYUFA
17GHDGH
18H94
19K9.
20M0S
21M1P
22PQEST
23PQQKQ
24PQUKI
25PRINS
267X8
27BOBZL
28CLFQK
295PM
orcididhttps://orcid.org/0000-0002-4108-5229
sort
creationdate20190713
titleThe relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
authorOshima, Megumi ; Jun, Min ; Ohkuma, Toshiaki ; Toyama, Tadashi ; Wada, Takashi ; Cooper, Mark E ; Hadjadj, Samy ; Hamet, Pavel ; Harrap, Stephen ; Mancia, Giuseppe ; Marre, Michel ; Williams, Bryan ; Chalmers, John ; Woodward, Mark ; Perkovic, Vlado
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1565t-ff07cb7974333cface6d9debdfaf9de24eaae3b5a8c9ad9195ee987ffd8bcb7c0
rsrctypearticles
prefilterarticles
languageeng
creationdate2019
topic
0Article
1Cardiovascular disease
2Cardiovascular diseases
3Creatinine
4Diabetes
5Diabetes mellitus
6Diabetes mellitus (non-insulin dependent)
7Diuretics
8eGFR slope
9End
10End-stage kidney disease
11End-stage renal disease
12Epidermal growth factor receptors
13Health aspects
14Health risk assessment
15Human Physiology
16Internal Medicine
17Kidney diseases
18Kidneys
19Medicine
20Medicine & Public Health
21Metabolic Diseases
22Mortality
23Regression analysis
24stage kidney disease
25Surrogate endpoint
26Type 2 diabetes
27Vascular diseases
toplevelpeer_reviewed
creatorcontrib
0Oshima, Megumi
1Jun, Min
2Ohkuma, Toshiaki
3Toyama, Tadashi
4Wada, Takashi
5Cooper, Mark E
6Hadjadj, Samy
7Hamet, Pavel
8Harrap, Stephen
9Mancia, Giuseppe
10Marre, Michel
11Williams, Bryan
12Chalmers, John
13Woodward, Mark
14Perkovic, Vlado
15ADVANCE Collaborative Group
16on behalf of the ADVANCE Collaborative Group
collection
0PubMed
1CrossRef
2Academic OneFile (A&I only)
3ProQuest Central (Corporate)
4Immunology Abstracts
5Health & Medical Collection
6ProQuest Central (purchase pre-March 2016)
7Medical Database (Alumni Edition)
8ProQuest Pharma Collection
9Public Health Database
10Hospital Premium Collection
11Hospital Premium Collection (Alumni Edition)
12ProQuest Central (Alumni) (purchase pre-March 2016)
13ProQuest Central (Alumni Edition)
14ProQuest Central
15Health Research Premium Collection
16Health Research Premium Collection (Alumni)
17AIDS and Cancer Research Abstracts
18ProQuest Health & Medical Complete (Alumni)
19Health & Medical Collection (Alumni Edition)
20Medical Database
21ProQuest One Academic Eastern Edition
22ProQuest One Academic
23ProQuest One Academic UKI Edition
24ProQuest Central China
25MEDLINE - Academic
26OpenAIRE (Open Access)
27OpenAIRE
28PubMed Central (Full Participant titles)
jtitleDiabetologia
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Oshima, Megumi
1Jun, Min
2Ohkuma, Toshiaki
3Toyama, Tadashi
4Wada, Takashi
5Cooper, Mark E
6Hadjadj, Samy
7Hamet, Pavel
8Harrap, Stephen
9Mancia, Giuseppe
10Marre, Michel
11Williams, Bryan
12Chalmers, John
13Woodward, Mark
14Perkovic, Vlado
aucorp
0ADVANCE Collaborative Group
1on behalf of the ADVANCE Collaborative Group
formatjournal
genrearticle
ristypeJOUR
atitleThe relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
jtitleDiabetologia
stitleDiabetologia
addtitleDiabetologia
date2019-07-13
risdate2019
volume62
issue11
spage1988
epage1997
pages1988-1997
issn0012-186X
eissn1432-0428
abstractAims/hypothesis Some studies have reported that annual change in eGFR (eGFR slope) is associated with the future risk of end-stage kidney disease, cardiovascular disease and death in general or chronic kidney disease cohorts. However, the benefits of using eGFR slopes for prediction of major clinical outcomes in diabetes are unclear. Methods We used data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial and the ADVANCE Post-Trial Observational Study (ADVANCE-ON). After excluding the first 4 months during which an acute fall in eGFR was induced by the initiation of an ACE inhibitor and diuretic combination agent, eGFR slopes were estimated by linear mixed models, using three measurements of eGFR at 4, 12 and 24 months after randomisation over 20 months, and categorised according to quartiles. Cox regression models were used to evaluate adjusted HRs for the study’s primary outcome, a composite of major renal events, major macrovascular events and all-cause mortality during the subsequent follow-up from 24 months after randomisation. Results A total of 8,879 participants (80%) were included in this cohort. The mean age was 65.6 years (SD 6.3), the mean eGFR was 75 ml min −1 (1.73 m) −2 (SD 17) and the median urinary albumin/creatinine ratio was 14 μg/mg (interquartile range 7–38). The mean eGFR slope was −0.63 ml min −1 (1.73 m) −2  year −1 (SD 1.75). Over a median follow-up of 7.6 years following the 20-month eGFR slope ascertainment period, 2,221 participants (25%) met the primary outcome. An annual substantial decrease in eGFR (lowest 25%, <−1.63 ml min −1 [1.73 m] −2  year −1 ) was significantly associated with the subsequent risk of the primary outcome (HR 1.30 [95% CI 1.17, 1.43]) compared with a stable change in eGFR (middle 50%, −1.63 to 0.33). An annual substantial increase in eGFR (highest 25%, >0.33) had no significant association with the risk of the primary outcome (HR 0.96 [95% CI 0.86, 1.07]). Conclusions/interpretation Our study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality. Trial registry number ClinicalTrials.gov registration no. NCT00145925 and no. NCT00949286
copBerlin/Heidelberg
pubSpringer Berlin Heidelberg
pmid31302707
doi10.1007/s00125-019-4948-4
orcididhttps://orcid.org/0000-0002-4108-5229
oafree_for_read